[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dr David Hasan, M.D.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100630892","phase-1-induced-suppression-of-platelet-activity-in-aneurysmal-subarachnoid-hemorrhage-management-2-ispasm-2-100630892",false,"NCT07493577","Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)","Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2","iSPASM-2","Inclusion:\n\n* Age 18-85\n* Baseline Modified Rankin Scale (mRS) 0-3 (pre-SAH)\n* SAH attributed to ruptured cerebral aneurysm\n* Admission Computed Tomography (CT) scan shows Modified Fisher grade 1-4 due to aSAH primarily in the supratentorial space\n* World Federation of Neurosurgical Societies (WFNS) scale grade ≤4 at randomization\n* Onset of symptoms of aSAH (ictus) occurred \\\u003C72 hours prior to presentation\n* If External Ventricular Drain (EVD) placed, placement is ≥12 hours prior to enrollment\n* All aneurysm(s) suspected to be responsible for the hemorrhage must be secured via Endovascular Coil Embolization with a post-embolization Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) prior to enrollment\n* Participant can be randomized within 48 hours of aneurysm treatment\n* Participant or participant's legally-authorized representative (LAR) has provided documented informed consent\n\nExclusion:\n\n* Angio-negative SAH, defined as a SAH with a digital subtraction angiogram that does not show an intracranial aneurysm\n* Surgical clipping prior of the ruptured aneurysm or any non-ruptured aneurysm on the same admission to enrollment\n* Remaining untreated aneurysm(s) that could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern\n* Uncontrollable hypertension (\\>180 systolic and\u002For \\>110 diastolic) that is not correctable prior to enrollment\n* Active internal bleeding, or history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month (30 days)\n* A medical diagnosis that requires continuous use of aspirin, clopidogrel, ticagrelor, or tirofiban during the study drug infusion\n* New parenchymal hemorrhage or new infarction larger than 15 cubic centimeters (cc) in volume by CT\n* Thrombolytic therapy within 24 hours prior to enrollment (alteplase, tenecteplase, or urokinase)\n* Previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial-venous malformation\n* Thrombocytopenia (platelet count \\\u003C100,000\u002Fmicroliter (µL) assuming clumping is ruled out\n* Allergy or intolerance to tirofiban\n* Pregnant or lactating\n* Chronic kidney disease with creatinine clearance (CrCl ≤ 30 milliliters per minute \\[ml\u002Fmin\\]) or acute kidney injury (AKI) at study screening. AKI is defined as:\n\n  i) Increase in serum creatinine by 0.3 milligrams per deciliter (mg\u002FdL) or more (26.5 micromoles per liter \\[μmol\u002FL\\] or more) within 48 hour period; OR ii) Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 day period; OR iii) Urine volume less than 0.5 ml\u002Fkg\u002Fhour for at least 6 hours","ALL","18 Years","85 Years",{"count":21,"type":22},82,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.",[29],"Aneurysmal Subarachnoid Hemorrhage",[31,32,33,34],"Subarachnoid Hemorrhage","Delayed Cerebral Ischemia","Tirofiban","Brain Aneurysm Rupture","NOT_YET_RECRUITING","2026-03-23",{"date":38,"type":39},"2026-03-25","ACTUAL",{"date":41,"type":22},"2026-07-23",{"date":43,"type":22},"2032-01-23",{"name":45,"class":46},"Dr David Hasan, M.D.","OTHER",2,""]